The compound you described, **2-(3-methanesulfonylamino-1-propenyl)pyrrolidin-4-ylthiol-6-(1-hydroxyethyl)-1-methyl-1-carbapen-2-em-3-carboxylic acid**, is a complex organic molecule that is **not a known, established chemical entity**. It's possible this is a hypothetical compound or a misrepresentation of an existing molecule.
Here's why it's difficult to determine its significance for research:
* **The name doesn't follow standard chemical nomenclature:** The way the molecule is named is unconventional and doesn't follow standard IUPAC nomenclature rules. This makes it challenging to decipher the exact structure.
* **Lack of information on its properties:** Without knowing the compound's structure, it's impossible to determine its physical and chemical properties. These are crucial for understanding its potential biological activity and research applications.
* **No reported research:** There's no published scientific literature mentioning this specific compound, indicating it hasn't been synthesized or investigated.
**If you have additional information about the compound, like a chemical structure or its potential origin, it would be helpful in understanding its significance. Otherwise, it's impossible to say why it would be important for research.**
**To clarify the compound's identity and research potential, you might consider:**
* **Checking your source:** Ensure the name is accurate and hasn't been misrepresented.
* **Seeking expert advice:** Consult a chemist or chemical information specialist who can help decipher the nomenclature and identify the compound.
DA 1131: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6442276 |
| MeSH ID | M0260511 |
| Synonym |
|---|
| da 1131 |
| 169285-98-7 |
| (4r,5s)-6-(1-hydroxyethyl)-3-[(3s,5s)-5-[(e)-3-(methanesulfonamido)prop-1-enyl]pyrrolidin-3-yl]sulfanyl-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid |
| 2-(3-methanesulfonylamino-1-propenyl)pyrrolidin-4-ylthiol-6-(1-hydroxyethyl)-1-methyl-1-carbapen-2-em-3-carboxylic acid |
| (4r,5s)-6-(1-hydroxyethyl)-4-methyl-3-(((3s,5s)-5-((e)-3-(methylsulfonamido)prop-1-en-1-yl)pyrrolidin-3-yl)thio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The pharmacokinetic parameters including tissue distribution and/or biliary excretion of DA-1131, a new carbapenem, were evaluated after intravenous (iv) administration to mice, rats, rabbits, and dogs." | ( Pharmacokinetics and tissue distribution of a new carbapenem DA-1131, after intravenous administration to mice, rats, rabbits and dogs. Kim, SH; Kwon, JW; Lee, MG, 1998) | 0.3 |
| " In addition, the concentration in plasma-time profile predicted that the DA-1131 data obtained from laboratory animals could be utilized to generate preliminary estimates of the pharmacokinetic parameters in humans." | ( Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Kim, SH; Kim, WB; Lee, MG, 1998) | 0.3 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (85.71) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.47) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||